Phase II trial with BCNU plus α-interferon in patients with recurrent high-grade gliomas

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 20, Issue 4, 1997, Pages 364-367

  Brandes, Alba Ariela ^a   Scelzi, Elvira ^a   Zampieri, Paolo ^a   Rigon, Alberto ^a   Rotilio, Antonino ^a   Amista, Pietro ^a   Berti, Franco ^a   Fiorentino, Mario V ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

BCNU; Central nervous system tumors; Chemotherapy; Cytoreductive surgery; Interferon

Indexed keywords

ALPHA INTERFERON; CARMUSTINE;

ADULT; AGED; ARTICLE; BLOOD BRAIN BARRIER; CANCER CONTROL; CANCER SURVIVAL; CELL PROLIFERATION; CELL TRANSFORMATION; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOSTASIS; DNA SYNTHESIS INHIBITION; DRUG UPTAKE; FEMALE; GLIOMA; HUMAN; MALE; PHASE 2 CLINICAL TRIAL; QUALITY OF LIFE; RECURRENT CANCER; REMISSION; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD PLATELETS; BRAIN NEOPLASMS; CARMUSTINE; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FEMALE; GLIOBLASTOMA; GLIOMA; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; INTERFERON-ALPHA; LEUKOPENIA; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RECOMBINANT PROTEINS; REMISSION INDUCTION; SURVIVAL RATE;

EID: 0030856633     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199708000-00008     Document Type: Article

References (17)

1. Brandes A, Soesan M, Fiorentino M. Medical treatment in high-grade malignant gliomas in adults: an overview. Anticancer Res 1991;11:719-28.
2. EORTC Brain Tumor Group: Effect of CCNU on survival rate of objective remission and duration of free interval in patients with malignant brain glioma. Final evaluation. Eur J Cancer 1978;14:851-6.
3. Stewart DJ. The role of chemotherapy in the treatment of gliomas in adults. Cancer Treat Rev 1989;16:129-60.
4. Lundblad D, Lundgre E. Block of a glioma cell line in S phase by interferon. Int J Cancer 1981;27:749-54.
5. Korosue K, Takeshita I, Mannoji H, et al. Interferon effects on multiplication, cytoplastic protein and GFAP content, and morphology in human glioma cells. J Neuro-Oncology 1983;1: 69-76.
6. Mihara Y, Kuratsu J, Takaki S, et al. Distribution of mouse interferon-B in normal and brain tumour-bearing. Acta Neurochir 1991;109:46-51.
7. Mahaley MS, Urso MB, Whaley RA. Immunobiology of primary intracranial tumors: Part X. Therapeutic efficacy of interferon in the treatment of recurrent gliomas. J Neurosurg 1985;719-25.
8. Creagan ET, Kovach JS, Long HJ, et al. Phase I study of recombinant leukocyte a human interferon combined with BCNU in selected patients with advanced cancer. J Clin Oncol 1986;4:408-13.
9. Buckner JC, Brown LD, Cascino TL, et al. Recombinant alpha-interferon (rIFNa) and BCNU in recurrent gliomas. J Biol Response Mod 1989;8:332-3.
10. Burger PC. Malignant astrocytic neoplasms: classification, pathology, anatomy and response to tratment. Semin Oncol 1986;13(1):16-26.
11. WHO handbook for reporting results of cancer treatment. WHO offset publication No. 48, Neoplasma 1980;20:37-46.
12. McDonald DR, Cascino TL, Clifford S. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277-80.
13. Kaplan EL, Meier P. Nonparametric estimation for incomplete observation. J Am Stat Assoc 1958;53:457-81.
14. Yung WKA, Prodos M, Levin VA, et al. Intravenous recombinant interferon beta in patients with recurrent malignant gliomas: a phase I/II Study. J Clin Oncol 1991;9:1945-9.
15. Buckner JC, Brown LD, Kuglet JW. Phase II evaluation of recombinant interpheron alpha and BCNU in recurrent glioma. J Neurosurg 1995;82:430-5.
16. Kornblith PL, Walker M. Chemotherapy for malignant gliomas. J Neurosurg 1988;68:1-17.
17. Ammirati M, Galicich JH, Arbit E, et al. Reoperation in the treatment of recurrent intracranial malignant gliomas. Neurosurgery 1987;21:607-13.